Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

Convergent Therapeutics Inc. announced that the US FDA has cleared the investigational new drug (IND) application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.